Cassava Sciences (NASDAQ:SAVA) posted its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.04, Bloomberg Earnings reports.
SAVA opened at $1.23 on Wednesday. The stock has a 50 day moving average of $1.34. Cassava Sciences has a twelve month low of $0.76 and a twelve month high of $2.99. The firm has a market cap of $21.18 million, a price-to-earnings ratio of -2.02 and a beta of 1.63.
Several equities research analysts recently weighed in on SAVA shares. ValuEngine upgraded Cassava Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright started coverage on Cassava Sciences in a report on Thursday, August 1st. They issued a “buy” rating and a $3.00 target price for the company. Finally, Maxim Group restated a “buy” rating on shares of Cassava Sciences in a report on Tuesday.
Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Story: How to track put option volume
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.